Business
Pfizer’s coronavirus vaccine gets OK from FDA advisers in US – Sydney Morning Herald
The FDA is widely expected to authorise the vaccine, developed with German partner BioNTech SE, for emergency use in the United States within days.
Pfizer has asked that the two-dose vaccine be approved for use in people aged 16 to 85. Several advisory panel members discussed whether 16 and 17-year-olds should be included in the recommendation because the risk to these individuals is low, and the evidence in the trial was scant.
In the end, they voted on the question as put them by the FDA, which included 16 to 17-year-olds. The FDA typically follows the advice of its expert panels, but is not bound to do so.
The panel also discussed concerns…
-
General19 hours agoGymnastics club in Berwick shuts down following child safety complaint
-
Noosa News22 hours agoSanta drops in for carols
-
Business23 hours agoHow much upside does Macquarie predict for Sonic Healthcare shares?
-
General20 hours agoTwo dead after separate road accidents in regional New South Wales